表紙
市場調査レポート

てんかん重積症:パイプライン分析

Status Epilepticus - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 200492
出版日 ページ情報 英文 58 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。
Back to Top
てんかん重積症:パイプライン分析 Status Epilepticus - Pipeline Review, H1 2016
出版日: 2016年02月24日 ページ情報: 英文 58 Pages
概要

てんかん重積症(SE)は、30分以上続く発作や、発作の間意識が戻らない状態を指します。 症候は局所、あるいは半身に知覚異常や無感覚が見られたり、視力低下や色彩豊かな幻覚という特徴のある焦点の視覚変化、 幻嗅や幻味、不規則な腹部の刺激などがあります。

当レポートでは、てんかん重積症の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

てんかん重積症 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Ligand Pharmaceuticals, Inc.
  • Sage Therapeutics

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • ADD-405008
  • fosphenytoin sodium
  • SAGE-217
  • SAGE-547
  • SAGE-689
  • SGE-102
  • Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus
  • TG-4155

最近のパイプライン動向

休止中のプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7567IDB

Summary

Global Markets Direct's, 'Status Epilepticus - Pipeline Review, H1 2016', provides an overview of the Status Epilepticus pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Status Epilepticus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Status Epilepticus and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Status Epilepticus
  • The report reviews pipeline therapeutics for Status Epilepticus by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Status Epilepticus therapeutics and enlists all their major and minor projects
  • The report assesses Status Epilepticus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Status Epilepticus

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Status Epilepticus
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Status Epilepticus pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Status Epilepticus Overview
  • Therapeutics Development
    • Pipeline Products for Status Epilepticus - Overview
    • Pipeline Products for Status Epilepticus - Comparative Analysis
  • Status Epilepticus - Therapeutics under Development by Companies
  • Status Epilepticus - Therapeutics under Investigation by Universities/Institutes
  • Status Epilepticus - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Status Epilepticus - Products under Development by Companies
  • Status Epilepticus - Products under Investigation by Universities/Institutes
  • Status Epilepticus - Companies Involved in Therapeutics Development
    • Marinus Pharmaceuticals, Inc.
    • RODES Inc.
    • Sage Therapeutics, Inc.
  • Status Epilepticus - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AMPX-0079 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fosphenytoin sodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ganaxolone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SAGE-217 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SAGE-689 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sepranolone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TG-4155 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Status Epilepticus - Recent Pipeline Updates
  • Status Epilepticus - Dormant Projects
  • Status Epilepticus - Product Development Milestones
    • Featured News & Press Releases
      • Dec 15, 2015: SAGE Updates Guidance for Top-Line Results of Phase 3 STATUS Trial of SAGE-547
      • Dec 02, 2015: SAGE to Present Poster Presentations on SAGE-547 at the American Epilepsy Society 69th Annual Meeting
      • Aug 17, 2015: SAGE Announces First Patient Treated in Phase 3 STATUS Trial of SAGE-547 in Super-Refractory Status Epilepticus
      • Aug 06, 2015: SAGE Receives Special Protocol Assessment for Phase 3 STATUS Trial of SAGE-547 in Super-Refractory Status Epilepticus
      • Jun 09, 2015: SAGE Therapeutics Announces Positive Top-Line Data in Exploratory Trial of SAGE-547 in Postpartum Depression
      • May 14, 2015: SAGE Therapeutics Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in Super-Refractory Status Epilepticus
      • Apr 22, 2015: Ligand Earns Milestone from SAGE Therapeutics for SAGE-547
      • Apr 20, 2015: SAGE Therapeutics Announces First Patient Treated Under Phase 3 Expanded Access Protocol to Evaluate SAGE-547 in Patients With Super-Refractory Status Epilepticus
      • Apr 09, 2015: SAGE Therapeutics presents preclinical data on SAGE-689 at Upcoming Scientific Conferences
      • Apr 09, 2015: SAGE Therapeutics presents Phase 1/2 clinical trial data on SAGE-547 at Upcoming Scientific Conferences
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Status Epilepticus, H1 2016
  • Number of Products under Development for Status Epilepticus - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Status Epilepticus - Pipeline by Marinus Pharmaceuticals, Inc., H1 2016
  • Status Epilepticus - Pipeline by RODES Inc., H1 2016
  • Status Epilepticus - Pipeline by Sage Therapeutics, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Status Epilepticus Therapeutics - Recent Pipeline Updates, H1 2016
  • Status Epilepticus - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Status Epilepticus, H1 2016
  • Number of Products under Development for Status Epilepticus - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top